Navigation Links
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Date:2/11/2008

ans on the importance of treating

I.V. pain and on the features and use of Zingo for their pediatric

patients. These initiatives will be complemented by Zingo co-promotion

and distribution partner Sagent Pharmaceuticals' representatives, who

will work primarily with hospital pharmacies.

-- Launched two initiatives aimed to improve peripheral venous access pain

management in children: RN VOICE (Registered Nurses for Venipuncture

Optimization through Increased Comfort and Education), a

multidisciplinary group of healthcare professionals led by nurses to

facilitate better management of venous access pain; and

http://www.manageIVpain.com, an interactive Web site designed for

parents and healthcare providers seeking to better manage peripheral

venous access pain in children.

-- Proceeded with plans to file a supplemental New Drug Application with

the FDA in the first quarter of 2008 to expand the Zingo label to

include adults, based on successful pivotal Phase 3 trial in

approximately 700 adult patients.

-- Signed exclusive license agreement with Sigma-Tau SpA for the marketing

and distribution of Zingo in six European countries: Italy, France,

Germany, Netherlands, Belgium and Luxembourg. Sigma-Tau will oversee

all necessary regulatory filings, and will be responsible for all

marketing and sales of Zingo in their territory.

-- Granted an exclusive license to Medical Futures, Inc. for the marketing

and distribution of Zingo in Canada. Under the terms of the license,

Medical Futures will be responsible for all regulatory filings,

marketing, distribution and sales in Canada.

-- Conducted webcast and briefing in New York City with financial analysts

and major investors to present plans for
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Anesiva Appoints Daniel Janney to Board of Directors
2. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
3. Anesiva Announces Completion of Common Stock Offering
4. Anesiva Raises $45 Million in Common Stock Offering
5. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
6. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... day, their baby stopped breathing, his collapsed bronchus blocking ... and Bryan Gionfriddo watched helplessly, just praying that somehow ... doctors said he had a good chance of not ... now 20-month-old son, Kaiba. "At that point, we were ... and run with it." , They found hope at ...
(Date:5/23/2013)... 23, 2013 Graphite Metallizing Corporation ... bushings mounted in stainless steel pillow blocks. This ... GRAPHALLOY with the application and installation versatility of ... Blocks work exceptionally well when submerged in ... liquids such as acids, alkalies, hydrocarbons, black liquor, ...
(Date:5/23/2013)... 23, 2013 The maker community is ... of inventions. They focus on learning practical skills while ... gravitate toward bringing their ideas to life via crowdfunding. ... works on making projects using biology. Glowing Plant has ... to make them glow with bioluminescence genes, and has ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... Calif., Aug. 30 Cepheid (Nasdaq:,CPHD) will present ... at the Four Seasons Hotel, Boston, September 5 ... and Senior Vice President, Finance and,Chief Financial Officer, ... ET on,September 7. The webcast, along with ...
... Aug. 30 Verenium,Corporation (Nasdaq: VRNM ), a ... the development of high-performance specialty,enzymes, announced today that Carlos ... be presenting at the Cowen and Company Clean,Energy Conference. ... ET,on Thursday, September 6, 2007 and will take place ...
... 30 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... and CEO will present at the 2007 UBS ... the Grand Hyatt New York on Wednesday,September 26 ... ) A live webcast of the presentation ...
Cached Biology Technology:Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 2Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference 3Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... the implications for the overall health, development, and ... primary role in ensuring that all students have ... per day of vigorous or moderate-intensity physical activity, ... Medicine. Recent estimates suggest that only about ... for promoting better health and development. The ...
(Date:5/23/2013)... medics have succeeded in treating cerebral palsy with autologous ... damage, a 2.5 year old boy had been in ... survival. Just two months after treatment with the cord ... the following months, the child learned to speak simple ... from a Korean study, dispel the long-held doubts about ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... is most well-known both for his book "On the Origin of ... do not think anything in my scientific life has given me ... of these plants." What could be more satisfying than ... to his studies of different forms of hermaphroditic flowers that occur ...
... , an internationally recognized expert at the University of ... been chosen by the U.S. Department of State to ... Miller is one of only ten persons selected for ... rigorous selection process, are highly accomplished in fields of ...
... gowns and bed sheets to match a patient,s skin color ... other health-related skin color changes, according to a new study ... patient, and then sees the patient again later, the doctor ... has changed color," said neurobiologist and study leader Mark Changizi, ...
Cached Biology News:'Different forms of flowers' continues to fascinate 2US Department of State names UCR entomologist a Jefferson Science Fellow 2US Department of State names UCR entomologist a Jefferson Science Fellow 3Nude-colored hospital gowns could help doctors better detect hard-to-see symptoms 2
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Biology Products: